Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Eur J Obstet Gynecol Reprod Biol. 2010 Jun;150(2):203-6. doi: 10.1016/j.ejogrb.2010.02.024. Epub 2010 Mar 4.
To compare the effectiveness and side effects of cabergoline with bromocriptine for the symptomatic treatment of cyclic mastalgia as a part of the premenstrual syndrome.
140 women with premenstrual mastalgia were enrolled in this randomised, open-label trial. Two groups were created (bromocriptine and cabergoline) and consisted of 61 and 67 patients respectively at the end of trial. Bromocriptine was administered 5 mg daily during second half of the menstrual cycle. Cabergoline was administered 0.5 mg weekly during the second half of the cycle. Relief of pain was evaluated using a visual analog scale (VAS). The mean percentage decrease in score for all patients in each group was calculated. A 50% or greater decrease at the end of the third month from the basal VAS score was accepted as a positive response to drug therapy. Data regarding side effects were collected systematically with review of a symptom diary.
The positive response rates to treatment were similar (bromocriptine 66.6% and cabergoline 68.4%). The pain reduction rates for each month were also similar. Moreover, the pain reduction rate was maximum in the second month of treatment for both groups. Vomiting (28%), nausea (39%) and headaches (23%) recorded in the bromocriptine group were significantly more frequent than vomiting (4.5%), nausea (20.9%) and headache (6%) recorded in the cabergoline group (p=0.023, p=0.001, p=0.006 respectively). A difference in the rate of dizziness was not statistically significant (26.4% vs. 14.9%). There was no correlation between the baseline breast pain score and prolactin level but post-treatment pain reduction was well correlated with prolactin level.
Cabergoline is as effective as bromocriptine for the treatment of cyclic mastalgia but has minimal side effects compared to bromocriptine.
比较卡麦角林与溴隐亭治疗经前期综合征周期性乳房痛的疗效和副作用。
本随机、开放标签试验纳入了 140 例经前期乳房痛患者。试验结束时，将患者分为两组（溴隐亭组和卡麦角林组），分别为 61 例和 67 例。溴隐亭组在月经周期后半期每天给予 5mg，卡麦角林组在月经周期后半期每周给予 0.5mg。采用视觉模拟评分（VAS）评估疼痛缓解情况。计算每组所有患者评分的平均百分比下降。从基础 VAS 评分的第 3 个月末评分下降 50%或以上被认为对药物治疗有阳性反应。系统收集了有关副作用的数据，并审查了症状日记。
两组治疗的阳性反应率相似（溴隐亭组 66.6%，卡麦角林组 68.4%）。每个月的疼痛缓解率也相似。此外，两组的疼痛缓解率在治疗的第二个月达到最大值。溴隐亭组出现的呕吐（28%）、恶心（39%）和头痛（23%）明显多于卡麦角林组（4.5%、20.9%和 6%）（p=0.023、p=0.001、p=0.006）。头晕的发生率差异无统计学意义（26.4% vs. 14.9%）。基线乳房疼痛评分与催乳素水平之间无相关性，但治疗后疼痛缓解与催乳素水平呈良好相关性。
卡麦角林治疗周期性乳房痛的疗效与溴隐亭相当，但副作用比溴隐亭少。
